DiMe Generated Content
Meet the ATA’s 12 Telehealth Innovators Challenge Finalists
February 26, 2023
DiMe, partners launch toolkit for DEI in digitised trials
February 15, 2023
Two Straightforward Ways To Improve DE&I In Clinical Trials
December 27, 2022
How Clinical Trials Can Thrive in the Digital Era
November 22, 2022
How pharma can thrive in the digital era
November 3, 2022
DiMe Physical Activity Measure
October 20, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
DiMe Research Committee working group discusses key considerations for generating evidence for clinical validity, regulatory pathways through which clinical validity evidence may be reviewed, and challenges that investigators may encounter while dealing with data from biometric monitoring technologies.
Recommendations for Defining and Reporting Adherence Measured by Miometric Monitoring Technologies: Systematic Review
DiMe Research Committee working group reviews methods and definitions by which adherence has been captured and reported using BioMets in order to identify gaps and provide recommendations to the field.
July 28, 2022
Considerations for Conducting Bring Your Own “Device” (BYOD) Clinical Studies
DiMe Research Committee working group explores the potential, risks, and key considerations for organizations to consider when using a “BYOD” approach in clinical research
July 28, 2022
Industry Voices—Virtual care should address transition points in our fragmented system
In partnership with IMPACT member Wellinks, DiMe leadership discuss how virtual-first care can improve patient experience and engagement across the care journey and optimize handoffs between care settings
July 27, 2022
Your Guide To Harnessing Clinical Trial Sensor Data Better
DiMe CEO, Jen Goldsack, describes the imperative for preparing for the use of sensor data at scale
July 26, 2022
New Toolkit Aims to Support Effective Virtual-First Care Transitions
The Digital Medicine Society and American Telemedicine Association have developed a new toolkit to support the integration of virtual and in-person healthcare.
June 28, 2022
FDA Diversity Plan Clinical Trials
A letter submitted on behalf of the Digital Medicine Society (DiMe) for consideration by the U.S. Food and Drug Administration (FDA) regarding Docket No. FDA-2021-D-0789 for “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability .”
June 2022
Contact Us
-
90 Canal Street, 4th Floor
Boston, Massachusetts 02114
